Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors
作者:Sheng Han、Yali Sang、Yan Wu、Yuan Tao、Christophe Pannecouque、Erik De Clercq、Chunlin Zhuang、Fen-Er Chen
DOI:10.1016/j.ejmech.2019.111874
日期:2020.1
fragment hopping approach is widely applied in drug development. A series of diarylpyrimidines (DAPYs) were obtained by hopping the thioacetamide scaffold to novel human immunodeficiency virus type 1 (HIV-1) nonnucleoside reversetranscriptaseinhibitors (NNRTIs) to address the cytotoxicity issue of Etravirine and Rilpivirine. Although the new compounds (11a-l) in the first-round optimization possessed less
Novel 1,3,4-trisubstituted pyrazolopyrimidine derivatives show potent antiproliferative activity in mantle cell lymphoma
作者:Guisen Zhao、Fansheng Ran、Lun Dong、Yang Liu
DOI:10.2174/1570180820666230602093051
日期:2023.6.2
Background: Pyrazolopyrimidine scaffold is an important pharmacophore in drug discovery. This pharmacophore has been reported to produce numerous biologicalactivities, of which anticancer is an important one. The development of novel pyrazolopyrimidine derivatives is of great importance for antitumor drug research. Objective: Compound 6, a pyrazolopyrimidine derivative reported by our group, showed
Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis, inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our investigation of a non-peptide, orally available FXa inhibitor, we found that a series of N-[(7-amidino-2-naphthyl)methyl]aniline derivatives possessed potent and selective inhibitory activities. Structure-activity relationship (SAR) of the substituent (R-1) on the central aniline moiety suggested that increasing lipophilicity caused a detrimental effect on anticoagulant activity (prothrombin time assay) in plasma. Several compounds bearing a hydrophilic substituent in R-1 showed not only potent FXa inhibitory activities but also high anticoagulant activities. The best compound in this series was sulfamoylacetic acid derivative 8o (YM-60828) which was a potent, selective and orally bioavailable FXa inhibitor and was chosen for clinical development. (C) 2002 Elsevier Science Ltd. All rights reserved.
Dicationic 2-fluorenonylcarbapenems: Potent anti-MRS agents with improved solubility and pharmacokinetic properties
作者:Mark L. Greenlee、Joanne B. Laub、Gregory P. Rouen、Frank DiNinno、Milton L. Hammond、Joann L. Huber、Jon G. Sundelof、Gail G. Hammond
DOI:10.1016/s0960-894x(99)00567-3
日期:1999.11
The synthesis and biological evaluation of a series of dicationic-substituted 2-fluorenonylcarbapenems is described. This class of compounds showed enhanced water solubility while maintaining potent activity against MRS. Introduction of a beta 1--methyl substituent was found to improve pharmacokinetics. (C) 1999 Elsevier Science Ltd. All rights reserved.
Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors
作者:Sheng Han、Yuan Lei、Christophe Pannecouque、Erik De Clercq、Chunlin Zhuang、Fener Chen
DOI:10.1016/j.cclet.2019.11.020
日期:2020.3
Two series of sulfur-containing diarylbenzopyrimidines are designed by the fragment combination of a thioacetamide with our previous disclosed DABP 3 and further oxidation. The best compound 6e with a sulfonyl scaffold displayed EC50 values of 0.0356 mu mol/L against WT and 0.0228 mu mol/L against HIV K103N mutant strain. More pronounced, it had a lower cytotoxicity (CC50 = 99.6 mu mol/L), higher selectivity index (SIWT = 2799, SIK103N = 4375) and better calculated logarithm of the octanol-water partition coefficient (cLogP) than the lead compound 3. Molecular docking and dynamics provided the binding modes of these compounds with reverse transcriptase, explaining their activity. Collectively, the new compounds could be candidates for anti-HIV drug discovery. (C) 2019 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.